Omnicell Company Profile (NASDAQ:OMCL)

About Omnicell (NASDAQ:OMCL)

Omnicell logoOmnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Healthcare Information Services
  • Sub-Industry: Health Care Technology
  • Symbol: NASDAQ:OMCL
  • CUSIP: 68213N10
  • Web:
  • Market Cap: $1.54 billion
  • Outstanding Shares: 37,163,000
Average Prices:
  • 50 Day Moving Avg: $40.81
  • 200 Day Moving Avg: $37.08
  • 52 Week Range: $30.33 - $42.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 20.24
  • P/E Growth: 1.95
Sales & Book Value:
  • Annual Revenue: $672.17 million
  • Price / Sales: 2.29
  • Book Value: $11.82 per share
  • Price / Book: 3.51
  • EBIDTA: $43.9 million
  • Net Margins: 1.24%
  • Return on Equity: 10.74%
  • Return on Assets: 5.31%
  • Debt-to-Equity Ratio: 0.50%
  • Current Ratio: 1.70%
  • Quick Ratio: 1.33%
  • Average Volume: 275,418 shs.
  • Beta: 0.76
  • Short Ratio: 9.35

Frequently Asked Questions for Omnicell (NASDAQ:OMCL)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Thursday, May, 4th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.36. The business earned $150.90 million during the quarter, compared to analysts' expectations of $152.63 million. Omnicell had a net margin of 1.24% and a return on equity of 10.74%. The business's revenue was down 12.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.35 earnings per share. View Omnicell's Earnings History.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY17 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $1.22-1.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.36. The company issued revenue guidance of $720-740 million, compared to the consensus revenue estimate of $748.71 million.Omnicell also updated its Q2 guidance to $0.21-0.27 EPS.

Where is Omnicell's stock going? Where will Omnicell's stock price be in 2017?

8 equities research analysts have issued 1-year price targets for Omnicell's shares. Their forecasts range from $40.00 to $55.00. On average, they expect Omnicell's share price to reach $46.50 in the next year. View Analyst Ratings for Omnicell.

What are analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:

  • 1. According to Zacks Investment Research, "Omnicell exited first quarter 2017 on a disappointing note with year-over-year decline in both earnings and revenues. We are also concerned about the company’s increasing cost of production and integration expenses. The escalating costs continue to dent margin performance. Weak hospital spending trends and tough competition also pose threats. Over the last one month, Omnicell’s shares were trading neck to neck with the Zacks Categorized Medical Information Systems industry. Post its first-quarter debacle; the company witnessed a nose dive in its share price which is currently trading much below the broader industry. Yet, the market is optimistic on the growing significance of medication non-adherence where Omnicell is making substantial expansion. The company is also progressing well with its three-pronged growth strategy. We are particularly looking forward to the launch of the XT Series in the quarter which should boost revenue and profitability down the line." (5/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on OMCL shares and increase our 12-month target price from $38 to $43. Our long-term DCF model now reflects slightly higher revenue growth and improved margins. We recently hosted investor meetings for management. Beyond its traditional equipment sales, OMCL is now focused on hospital pharmacy performance in order to improve workflow efficiencies. Separately, we spoke with an early adopter/development partner of the newly-launched XT platform. While this is just one data point, we believe that the XT launch will result in new revenue opportunities for the company as it upgrades existing customers over the next 3 to 7 years." (3/6/2017)

Who are some of Omnicell's key competitors?

Who owns Omnicell stock?

Omnicell's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.14%), Vanguard Group Inc. (5.03%), Dimensional Fund Advisors LP (4.77%), Champlain Investment Partners LLC (4.60%), Conestoga Capital Advisors LLC (4.10%) and Bank of New York Mellon Corp (3.22%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Who sold Omnicell stock? Who is selling Omnicell stock?

Omnicell's stock was sold by a variety of institutional investors in the last quarter, including King Luther Capital Management Corp, IronBridge Capital Management LP, Tygh Capital Management Inc., DnB Asset Management AS, Morgan Stanley, Nicholas Company Inc., JPMorgan Chase & Co. and Geode Capital Management LLC. Company insiders that have sold Omnicell stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Randall A Lipps, Robin Gene Seim and Sara J White. View Insider Buying and Selling for Omnicell.

Who bought Omnicell stock? Who is buying Omnicell stock?

Omnicell's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eagle Asset Management Inc., Wells Fargo & Company MN, Tributary Capital Management LLC, Westfield Capital Management Co. LP, Conestoga Capital Advisors LLC, Summit Creek Advisors LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Omnicell.

How do I buy Omnicell stock?

Shares of Omnicell can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Omnicell stock cost?

One share of Omnicell stock can currently be purchased for approximately $41.50.

Analyst Ratings

Consensus Ratings for Omnicell (NASDAQ:OMCL) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $46.50 (12.05% upside)

Analysts' Ratings History for Omnicell (NASDAQ:OMCL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017CIBCBoost Price TargetOutperform$43.00 -> $53.00LowView Rating Details
4/25/2017Oppenheimer Holdings Inc.Reiterated RatingOutperform$43.00 -> $53.00HighView Rating Details
4/21/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$40.00HighView Rating Details
3/6/2017Cantor FitzgeraldBoost Price TargetOverweight$38.00 -> $43.00N/AView Rating Details
1/19/2017Dougherty & CoInitiated CoverageBuy$44.00N/AView Rating Details
12/6/2016Benchmark Co.Boost Price TargetBuy$39.00 -> $55.00N/AView Rating Details
9/8/2016SidotiDowngradeBuy -> Neutral$43.00N/AView Rating Details
7/29/2016FBR & CoBoost Price TargetOutperform$40.00 -> $41.00N/AView Rating Details
3/21/2016Topeka Capital MarketsLower Price TargetBuy$38.00 -> $37.00N/AView Rating Details
11/1/2015Cowen and CompanyReiterated RatingMarket Perform$37.00 -> $29.00N/AView Rating Details
6/18/2015StephensInitiated CoverageOutperform$44.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Omnicell (NASDAQ:OMCL)
Earnings by Quarter for Omnicell (NASDAQ:OMCL)
Earnings History by Quarter for Omnicell (NASDAQ:OMCL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.30)$0.06$152.63 million$150.90 millionViewListenView Earnings Details
2/15/2017Q4 2016$0.41$0.37$179.28 million$171.97 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.40$179.75 million$179.40 millionViewListenView Earnings Details
7/28/2016Q216$0.32$0.38$170.89 million$175.60 millionViewListenView Earnings Details
4/28/2016Q116$0.26$0.35$167.18 million$171.00 millionViewListenView Earnings Details
2/4/2016Q415$0.39$0.40$126.89 million$130.30 millionViewListenView Earnings Details
10/29/2015Q315$0.36$0.36$128.50 million$125.20 millionViewListenView Earnings Details
7/30/2015Q215$0.32$0.28$121.35 million$112.80 millionViewListenView Earnings Details
4/30/2015Q115$0.23$0.29$112.00 million$16.20 millionViewN/AView Earnings Details
2/3/2015Q414$0.33$0.39$114.65 million$121.50 millionViewListenView Earnings Details
10/30/2014Q314$0.31$0.30$106.10 million$112.50 millionViewListenView Earnings Details
7/31/2014Q214$0.29$0.30$103.23 million$105.10 millionViewListenView Earnings Details
5/1/2014Q114$0.24$0.26$97.49 million$101.80 millionViewListenView Earnings Details
2/4/2014Q413$0.28$0.29$101.13 million$105.80 millionViewListenView Earnings Details
10/31/2013Q313$0.28$0.31$94.96 million$94.03 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.25$0.27$92.42 million$93.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.19$0.21$87.20 million$87.11 millionViewN/AView Earnings Details
1/31/2013Q4 2012$0.25$0.25$87.31 million$90.16 millionViewN/AView Earnings Details
10/25/2012$0.22$0.29ViewN/AView Earnings Details
8/1/2012$0.18$0.20ViewN/AView Earnings Details
5/2/2012$0.13$0.13ViewN/AView Earnings Details
1/26/2012$0.16$0.19ViewN/AView Earnings Details
10/27/2011$0.16$0.16ViewN/AView Earnings Details
7/28/2011$0.13$0.15ViewN/AView Earnings Details
5/2/2011$0.10$0.11ViewN/AView Earnings Details
1/27/2011$0.12$0.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omnicell (NASDAQ:OMCL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.12$0.12$0.12
Q4 20171$0.32$0.32$0.32
(Data provided by Zacks Investment Research)


Dividend History for Omnicell (NASDAQ:OMCL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Omnicell (NASDAQ:OMCL)
Insider Ownership Percentage: 3.75%
Institutional Ownership Percentage: 94.34%
Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)
Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)
Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Dan S JohnstonEVPSell16,400$40.67$666,988.00View SEC Filing  
5/9/2017J Christopher DrewVPSell10,625$40.97$435,306.25View SEC Filing  
4/25/2017Randall A LippsChairmanSell18,200$41.00$746,200.00View SEC Filing  
3/10/2017Gary S PetersmeyerDirectorSell2,658$37.45$99,542.10View SEC Filing  
2/21/2017Sara J WhiteDirectorSell3,443$38.06$131,040.58View SEC Filing  
11/18/2016Dan S JohnstonEVPSell8,850$33.65$297,802.50View SEC Filing  
11/18/2016Jorge R TaborgaVPSell2,068$33.66$69,608.88View SEC Filing  
11/8/2016J Christopher DrewVPSell20,000$31.95$639,000.00View SEC Filing  
9/12/2016Gary S PetersmeyerDirectorSell2,000$37.98$75,960.00View SEC Filing  
9/8/2016Gary S PetersmeyerDirectorSell2,400$39.39$94,536.00View SEC Filing  
9/6/2016Gary S PetersmeyerDirectorSell2,000$39.02$78,040.00View SEC Filing  
9/2/2016Gary S PetersmeyerDirectorSell3,000$38.52$115,560.00View SEC Filing  
8/19/2016Dan S JohnstonEVPSell8,850$36.93$326,830.50View SEC Filing  
8/19/2016Jorge R TaborgaVPSell1,778$36.92$65,643.76View SEC Filing  
8/11/2016Randall A LippsChairmanSell37,425$37.37$1,398,572.25View SEC Filing  
8/9/2016J Christopher DrewVPSell15,000$37.89$568,350.00View SEC Filing  
8/9/2016James T JudsonDirectorSell6,250$37.98$237,375.00View SEC Filing  
8/4/2016Gary S PetersmeyerDirectorSell8,750$37.84$331,100.00View SEC Filing  
7/29/2016Jorge R TaborgaVPSell10,023$40.00$400,920.00View SEC Filing  
7/6/2016Robin Gene SeimEVPSell5,302$34.75$184,244.50View SEC Filing  
7/1/2016Robin Gene SeimEVPSell3,645$35.00$127,575.00View SEC Filing  
6/6/2016Jorge R TaborgaVPSell25,979$33.00$857,307.00View SEC Filing  
5/24/2016Gary S PetersmeyerDirectorSell6,250$31.22$195,125.00View SEC Filing  
5/20/2016Dan S JohnstonEVPSell8,850$30.73$271,960.50View SEC Filing  
5/20/2016Jorge R TaborgaVPSell1,933$30.73$59,401.09View SEC Filing  
5/10/2016J Christopher DrewVPSell15,000$31.63$474,450.00View SEC Filing  
5/5/2016Sara J WhiteDirectorSell2,000$31.76$63,520.00View SEC Filing  
4/29/2016Robin Gene SeimEVPSell6,407$31.00$198,617.00View SEC Filing  
4/26/2016Jorge R TaborgaVPSell23,827$30.00$714,810.00View SEC Filing  
4/26/2016Robin Gene SeimEVPSell767$30.00$23,010.00View SEC Filing  
2/19/2016Dan S JohnstonEVPSell8,850$27.41$242,578.50View SEC Filing  
2/19/2016Jorge R TaborgaVPSell1,685$27.42$46,202.70View SEC Filing  
2/11/2016Randall A. LippsCEOSell40,000$27.81$1,112,400.00View SEC Filing  
2/9/2016J Christopher DrewVPSell15,000$27.57$413,550.00View SEC Filing  
12/18/2015Nhat H. NgoVPSell4,069$28.71$116,820.99View SEC Filing  
11/17/2015Dan S. JohnstonVPSell2,500$28.00$70,000.00View SEC Filing  
11/10/2015J Christopher DrewVPSell25,000$26.79$669,750.00View SEC Filing  
11/9/2015Dan S. JohnstonVPSell2,700$27.29$73,683.00View SEC Filing  
10/13/2015Gary S. PetersmeyerDirectorSell670$31.66$21,212.20View SEC Filing  
8/13/2015Robin Gene SeimCFOSell23,946$35.63$853,195.98View SEC Filing  
7/1/2015Robin Gene SeimCFOSell19,582$37.84$740,982.88View SEC Filing  
6/17/2015Nhat H NgoVPSell4,067$38.78$157,718.26View SEC Filing  
6/2/2015James T JudsonDirectorSell8,032$36.83$295,818.56View SEC Filing  
6/2/2015Nhat H NgoVPSell6,375$36.80$234,600.00View SEC Filing  
5/26/2015Sara J WhiteDirectorSell4,000$36.25$145,000.00View SEC Filing  
5/7/2015Dan S JohnstonVPSell7,715$34.25$264,238.75View SEC Filing  
2/12/2015J Christopher DrewVPSell25,000$34.62$865,500.00View SEC Filing  
2/6/2015Dan S JohnstonVPSell6,552$33.29$218,116.08View SEC Filing  
2/2/2015James T JudsonDirectorSell5,000$31.61$158,050.00View SEC Filing  
1/13/2015Gary S PetersmeyerDirectorSell670$31.31$20,977.70View SEC Filing  
1/2/2015James T JudsonDirectorSell5,000$32.36$161,800.00View SEC Filing  
1/2/2015Robin Gene SeimCFOSell1,948$32.36$63,037.28View SEC Filing  
12/17/2014Marga Ortigas-WedekindVPSell4,080$32.20$131,376.00View SEC Filing  
12/15/2014Gary S PetersmeyerDirectorSell670$33.25$22,277.50View SEC Filing  
12/8/2014Nhat H NgoVPSell1,754$32.89$57,689.06View SEC Filing  
12/1/2014James T JudsonDirectorSell5,000$31.94$159,700.00View SEC Filing  
11/12/2014Randy D LindholmDirectorSell5,000$31.72$158,600.00View SEC Filing  
11/11/2014J Christopher DrewVPSell37,500$31.86$1,194,750.00View SEC Filing  
11/7/2014Dan S JohnstonVPSell27,625$31.74$876,817.50View SEC Filing  
11/3/2014James T JudsonDirectorSell5,000$32.27$161,350.00View SEC Filing  
10/3/2014Nhat H NgoVPSell2,275$28.00$63,700.00View SEC Filing  
10/1/2014James T JudsonDirectorSell5,000$27.02$135,100.00View SEC Filing  
9/15/2014Jorge R TaborgaVPSell944$26.37$24,893.28View SEC Filing  
9/15/2014Robin Gene SeimCFOSell9,347$26.32$246,013.04View SEC Filing  
9/2/2014James T JudsonDirectorSell5,000$28.18$140,900.00View SEC Filing  
9/2/2014Robin Gene SeimCFOSell27,500$28.19$775,225.00View SEC Filing  
8/26/2014Dan S JohnstonVPSell6,250$28.00$175,000.00View SEC Filing  
8/26/2014James T JudsonDirectorSell9,913$27.91$276,671.83View SEC Filing  
7/9/2014Robin Gene SeimCFOSell2,442$28.21$68,888.82View SEC Filing  
7/1/2014James T JudsonDirectorSell5,000$29.28$146,400.00View SEC Filing  
6/26/2014Marga Ortigas-WedekindVPSell2,961$28.17$83,411.37View SEC Filing  
6/25/2014Nhat H NgoVPSell2,274$28.00$63,672.00View SEC Filing  
6/17/2014Nhat H NgoVPSell1,420$27.70$39,334.00View SEC Filing  
6/10/2014Nhat H NgoVPSell1,964$26.38$51,810.32View SEC Filing  
6/2/2014Gary S PetersmeyerDirectorSell5,000$26.45$132,250.00View SEC Filing  
5/21/2014Gary PetersmeyerDirectorSell2,000$26.51$53,020.00View SEC Filing  
5/13/2014J Christopher DrewVPSell37,500$26.08$978,000.00View SEC Filing  
5/7/2014Dan JohnstonVPSell4,000$25.25$101,000.00View SEC Filing  
5/1/2014James JudsonDirectorSell5,000$26.24$131,200.00View SEC Filing  
4/8/2014Nhat NgoVPSell1,002$27.40$27,454.80View SEC Filing  
3/18/2014Marga Ortigas-WedekindVPSell5,880$30.00$176,400.00View SEC Filing  
3/18/2014Randall LippsCEOSell124,910$29.89$3,733,559.90View SEC Filing  
12/18/2013Nhat NgoVPSell1,462$24.43$35,716.66View SEC Filing  
12/18/2013Randall LippsCEOSell64,739$24.30$1,573,157.70View SEC Filing  
12/3/2013Dan JohnstonVPSell73,419$23.24$1,706,257.56View SEC Filing  
11/11/2013Randy LindholmDirectorSell3,587$23.00$82,501.00View SEC Filing  
11/7/2013Dan JohnstonVPSell8,000$22.99$183,920.00View SEC Filing  
10/23/2013Robin Gene SeimCFOSell7,664$24.50$187,768.00View SEC Filing  
10/21/2013Robin Gene SeimCFOSell9,349$23.76$222,132.24View SEC Filing  
10/1/2013James T JudsonDirectorSell5,000$23.66$118,300.00View SEC Filing  
9/24/2013Randall LippsCEOSell68,204$25.00$1,705,100.00View SEC Filing  
9/23/2013Marga Ortigas-WedekindVPSell4,000$25.00$100,000.00View SEC Filing  
9/23/2013Randall LippsCEOSell5,083$25.00$127,075.00View SEC Filing  
9/20/2013Robin Gene SeimCFOSell27,500$24.35$669,625.00View SEC Filing  
9/18/2013Randall LippsCEOSell64,453$23.67$1,525,602.51View SEC Filing  
9/4/2013Nhat H NgoVPSell7,362$24.00$176,688.00View SEC Filing  
9/3/2013James JudsonDirectorSell5,000$22.77$113,850.00View SEC Filing  
8/20/2013James JudsonDirectorSell11,724$22.74$266,603.76View SEC Filing  
8/13/2013J Christopher DrewVPSell20,000$22.83$456,600.00View SEC Filing  
8/12/2013Donald WegmillerDirectorSell34,976$22.87$799,901.12View SEC Filing  
8/7/2013Dan JohnstonVPSell8,000$22.92$183,360.00View SEC Filing  
8/6/2013Randall LippsCEOSell5,321$23.00$122,383.00View SEC Filing  
8/2/2013Randall A LippsCEOSell25,000$22.50$562,500.00View SEC Filing  
8/1/2013James JudsonDirectorSell5,000$21.00$105,000.00View SEC Filing  
7/19/2013Nhat H NgoVPSell41,875$21.00$879,375.00View SEC Filing  
7/19/2013Randall A LippsCEOSell5,080$21.00$106,680.00View SEC Filing  
7/1/2013James T JudsonDirectorSell5,000$20.46$102,300.00View SEC Filing  
7/1/2013Robin Gene SeimCFOSell13,032$20.42$266,113.44View SEC Filing  
6/28/2013Marga Ortigas-WedekindVPSell4,545$20.00$90,900.00View SEC Filing  
6/28/2013Randall A LippsCEOSell25,000$20.00$500,000.00View SEC Filing  
6/21/2013Nhat H NgoVPSell3,459$19.01$65,755.59View SEC Filing  
6/18/2013Randall A LippsCEOSell66,378$19.10$1,267,819.80View SEC Filing  
6/10/2013Randy D LindholmDirectorSell23,901$19.14$457,465.14View SEC Filing  
6/4/2013Robin Gene SeimCFOSell25,000$18.72$468,000.00View SEC Filing  
5/22/2013Gary S PetersmeyerDirectorSell2,750$18.10$49,775.00View SEC Filing  
5/16/2013J Christopher DrewVPSell26,000$18.69$485,940.00View SEC Filing  
5/14/2013J Christopher DrewVPSell26,000$18.45$479,700.00View SEC Filing  
5/10/2013Sara J WhiteDirectorSell7,200$18.50$133,200.00View SEC Filing  
5/7/2013Dan S JohnstonVPSell8,000$18.44$147,520.00View SEC Filing  
12/3/2012Gary S PetersmeyerDirectorSell1,359$15.17$20,616.03View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Omnicell (NASDAQ:OMCL)
Latest Headlines for Omnicell (NASDAQ:OMCL)
DateHeadline logoOmnicell, Inc. (OMCL) Given Average Rating of "Buy" by Analysts - May 23 at 12:30 PM logoOmnicell, Inc. – Value Analysis (NASDAQ:OMCL) : May 22, 2017 - May 22 at 6:14 PM logoOmnicell, Inc. (OMCL) EVP Dan S. Johnston Sells 16,400 Shares - May 19 at 7:58 PM logoOmnicell, Inc. breached its 50 day moving average in a Bullish Manner : OMCL-US : May 19, 2017 - May 19 at 11:48 AM logoZacks Investment Research Lowers Omnicell, Inc. (OMCL) to Sell - May 10 at 1:00 PM logoInsider Selling: Omnicell, Inc. (OMCL) VP Sells 10,625 Shares of Stock - May 9 at 7:42 PM logoOmnicell Adds to Product Offerings in Canada Through Agreement with McKesson Canada - May 9 at 11:18 AM logoOmnicell (OMCL) Earning Somewhat Positive Press Coverage, AlphaOne Reports - May 9 at 12:51 AM logo Analysts Anticipate Omnicell, Inc. (OMCL) Will Post Earnings of $0.12 Per Share - May 8 at 2:22 PM logoEdited Transcript of OMCL earnings conference call or presentation 4-May-17 12:30pm GMT - May 8 at 12:11 PM logoTheStreet Downgrades Omnicell, Inc. (OMCL) to C+ - May 7 at 11:52 PM logoSomewhat Favorable Press Coverage Very Likely to Affect Omnicell (OMCL) Stock Price - May 6 at 12:32 AM logoInvestor Network: Omnicell, Inc. to Host Earnings Call - May 4 at 7:11 PM logoOmnicell Announces First Quarter 2017 Results - May 4 at 7:11 PM logoOmnicell, Inc. (OMCL) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS - May 4 at 5:26 PM logoOmnicell, Inc. (OMCL) Issues Q2 Earnings Guidance - May 4 at 10:17 AM logoOmnicell, Inc. (OMCL) Releases FY17 Earnings Guidance - May 4 at 10:17 AM logoOmnicell reports 1Q loss - May 4 at 9:29 AM logoSomewhat Favorable Press Coverage Likely to Impact Omnicell (OMCL) Share Price - May 3 at 1:05 AM logoSouthcoast Health Selects Omnicell's Medication Management and Analytics Solutions for Installation Across Multiple Facilities - May 2 at 11:13 AM logoOmnicell Announces Launch of XT Cabinets for AcuDose-Rx Customers - May 1 at 12:05 PM logoOmnicell (OMCL) Given Daily News Impact Score of 0.32 - April 29 at 10:22 PM logoOmnicell, Inc. (OMCL) Receives Average Rating of "Buy" from Analysts - April 28 at 1:48 PM logoOmnicell to Release First Quarter 2017 Earnings Results on May 4, 2017 - April 27 at 7:31 PM logoOmnicell (OMCL) Receiving Positive Media Coverage, AlphaOne Reports - April 27 at 1:07 AM logoOmnicell, Inc. (OMCL) PT Raised to $53.00 at CIBC - April 26 at 7:46 PM logoRandall A. Lipps Sells 18,200 Shares of Omnicell, Inc. (OMCL) Stock - April 26 at 2:52 PM logoOmnicell's (OMCL) "Outperform" Rating Reiterated at Oppenheimer Holdings Inc. - April 25 at 2:02 PM logoNorth Memorial Health Selects Omnicell's Medication Management Solutions to Support Increased Safety and Efficiency Throughout the Hospital - April 25 at 11:42 AM logoOmnicell (OMCL) Getting Somewhat Favorable News Coverage, Report Shows - April 23 at 8:33 PM logoOmnicell, Inc. (OMCL) Lowered to Neutral at Piper Jaffray Companies - April 21 at 11:33 PM logoOmnicell (OMCL) Announces Acquisition of InPharmics - April 20 at 7:09 PM logoOmnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $151.88 Million - April 19 at 10:21 AM logoOmnicell Acquires InPharmics - April 19 at 10:06 AM logo Brokerages Anticipate Omnicell, Inc. (OMCL) Will Post Earnings of -$0.30 Per Share - April 17 at 4:30 PM logoSomewhat Positive Press Coverage Very Likely to Impact Omnicell (OMCL) Share Price - April 16 at 2:15 PM logoSomewhat Positive Press Coverage Somewhat Likely to Impact Omnicell (OMCL) Stock Price - April 13 at 3:52 PM logoOmnicell Medication Adherence Named a 50+ Innovation Leader - April 12 at 7:56 PM logoOmnicell's Aesynt Buyout Looks Promising amid Several Woes - April 7 at 7:25 PM logoOmnicell's Aesynt Buyout Looks Promising amid Several Woes - Nasdaq - April 7 at 11:41 AM logoOmnicell's Aesynt Buyout Looks Promising amid Several Woes - April 7 at 11:41 AM logoWhy Is Omnicell (OMCL) Up 3% Since the Last Earnings Report? - Nasdaq - March 22 at 7:01 PM logoOmnicell's Newest Automated Dispensing Solutions to Be Showcased at the European Association of Hospital Pharmacists Congress - March 22 at 9:09 AM logoWhy Is Omnicell (OMCL) Up 3% Since the Last Earnings Report? - March 21 at 11:16 AM logoOmnicell Supports Pharmacy Advancement through Unrestricted Grant - March 20 at 9:48 AM logoInsider Selling: Omnicell, Inc. (OMCL) Director Sells 2,658 Shares of Stock - March 10 at 7:37 PM logoOMNICELL, INC Financials - March 4 at 7:04 PM logoPost Earnings Coverage as WebMD Net Income Surged 32%; Revenue Gained 8% - March 2 at 8:52 AM logoRBC Says These Top Health Care Stocks Could Be 2017 Takeover Candidates - March 2 at 8:52 AM logoOMNICELL, INC Files SEC form 10-K, Annual Report - March 1 at 10:24 AM



Omnicell (OMCL) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff